Scientists from the Pharmacomodulators Synthesis group & Laboratory of Pharmaceutical Pharmacology have reported that isoselenazolium salts may be a promising platform for the development of potent drug candidates for anticancer therapy that impact mitochondrial pyruvate-dependent metabolism in breast cancer cells. The article is published in the journal Scientific Reports (IF=3.998, 2019).
Marina Makrecka-Kuka, Pavels Dimitrijevs, Ilona Domracheva, Kristaps Jaudzems, Maija Dambrova, Pavel Arsenyan.
Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production.
Sci Rep. 2020, 10, 21595. DOI: 10.1038/s41598-020-78620-8
This work was supported by the Latvian Institute of Organic Synthesis internal grant (IG-2020-01 for Pavels Dimitrijevs) and SAM project Nr. 1.1.1.1/19/A/016.